The experience of follicular occlusion syndrome treatment with tumor necrosis factor inhibitors

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Follicular occlusion syndrome consists of several conditions that share similar pathophysiology involving infundibular follicular occlusion and secondary inflammatory cascade. This syndrome includes hidradenitis suppurativa, dissecting cellulitis of the scalp, acne conglobata and pilonidal sinus. They can develop independently or as a component of a syndrome in different combinations.

We are the first to present a clinical case of follicular occlusion tetrad and intermediate therapy outcome with tumor necrosis factor inhibitors. We also provide a full and updated review of the literature on the etiology and pathogenesis, diagnosis and treatment of similar syndromic conditions.

Currently, there is no reliable algorithm of treatment for patients with follicular occlusion syndrome, which underlines the importance of further studies. The presented clinical case confirms the need for timely administration of genetically-engineered biological drugs to patients with diseases of the follicular occlusion group (before sinus tract formation).

作者简介

Natalya Teplyuk

The First Sechenov Moscow State Medical University (Sechenov University)

Email: teplyukn@gmail.com
ORCID iD: 0000-0002-5800-4800
SPIN 代码: 8013-3256

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 8-2 Trubetskaya street, 119991 Moscow

Svetlana Konchina

The First Sechenov Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: konchina.svetlana@yandex.ru
ORCID iD: 0000-0003-2038-1472

Student

俄罗斯联邦, 8-2 Trubetskaya street, 119991 Moscow

Anna Pirogova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: annese@mail.ru
ORCID iD: 0000-0002-2246-1321
SPIN 代码: 1419-2147

MD, Graduate Student

俄罗斯联邦, 8-2 Trubetskaya street, 119991 Moscow

参考

  1. Vasanth V, Chandrashekar BS. Follicular occlusion tetrad. Indian Dermatol Online J. 2014;5(4):491. doi: 10.4103/2229-5178.142517
  2. Montes LF, Curtis AC. The follicular occlusion triad. Postgraduate Med. 1968;43(2):108–112. doi: 10.1080/00325481.1968.11693144
  3. Rossi FA, Magri CG, Muscianese F, et al. Are dissecting cellulitis and hidradenitis suppurativa different diseases? Clin Dermatol. 2021;39(3):496–499. doi: 10.1016/J.CLINDERMATOL.2021.01.002
  4. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Academy Dermatol Venereol. 2015;29(4):619–644. doi: 10.1111/JDV.12966
  5. Ovadja ZN, Schuit MM, van der Horst CM, Lapid O. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. British J Dermatol. 2019;181(2):344–349. doi: 10.1111/bjd.17588
  6. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Academy Dermatol. 2020;82(5):1045–1058. doi: 10.1016/J.JAAD.2019.08.090
  7. Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. British J Dermatol. 2020;183(6):999–1010. doi: 10.1111/bjd.19556
  8. Van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. J Am Academy Dermatol. 2015;73(5):S23–S26. doi: 10.1016/j.jaad.2015.07.047
  9. Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary of North American Hair Research Society (NAHRS): Sponsored workshop on cicatricial alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Academy Dermatol. 2003;48(1):103–110. doi: 10.1067/mjd.2003.68
  10. Takahashi T, Yamasaki K, Terui H, et al. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases. J Dermatol. 2019;46(9):802–807. doi: 10.1111/1346-8138.14998
  11. Scheinfeld N. Dissecting cellulitis (perifolliculitis capitis abscedens et suffodiens): A comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J. 2014;20(5):22692. doi: 10.5070/D3205022692
  12. Hafsi W, Arnold DL, Badri T. Acne Conglobata. J Royal Soc Med. 2022;30(11):1338–1341. doi: 10.1177/003591573703001110
  13. Jemec GB, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193(3):203–206. doi: 10.1159/000246246
  14. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. British J Dermatol. 1999;140(1):90–95. doi: 10.1046/J.1365-2133.1999.02613.X
  15. Williams CN, Cohen M, Ronan SG, Lewandowski CA. Dissecting cellulitis of the scalp. Plastic Reconstructive Sur. 1986;77(3):378–382. doi: 10.1097/00006534-198603000-00005
  16. De Parades V, Bouchard D, Janier M, Berger A. Pilonidal sinus disease. J Visceral Sur. 2013;150(4):237–247. doi: 10.1016/j.jviscsurg.2013.05.006
  17. Bettoli V, Join-Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):81–89. doi: 10.1016/J.DET.2015.08.013
  18. Stoodley P. Evidence for a biofilm-based treatment strategy in the management of chronic hidradenitis suppurativa. British J Dermatol. 2017;176(4):855–856. doi: 10.1111/BJD.15256
  19. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, intralesional, and systemic medical management. J Am Academy Dermatol. 2019;81(1):91–101. doi: 10.1016/J.JAAD.2019.02.068
  20. Kamp S, Fiehn AM, Stenderup K, et al. Hidradenitis suppurativa: A disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. British J Dermatol. 2011;164(5):1017–1022. doi: 10.1111/J.1365-2133.2011.10224.X
  21. Pastuszka M, Kaszuba A. Acitretin in psoriasis treatment: Recommended treatment regimens. Postep Dermatol Alergol. 2012;29(2):94–103.
  22. Verdolini R, Simonacci F, Menon S, et al. Alitretinoin: A useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150(2):155–162.
  23. Prasad SC, Bygum A. Successful Treatment with alitretinoin of dissecting cellulitis of the scalp in Keratitis-ichthyosis-deafness syndrome. Acta Derm Venereol. 2013;93(4):473–474. doi: 10.2340/00015555-1499
  24. Thomas J, Aguh C. Approach to treatment of refractory dissecting cellulitis of the scalp: A systematic review. J Dermatolog Treat. 2019;32(2):144–149. doi: 10.1080/09546634.2019.1642441
  25. Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: A little help along the way. J Eur Academy Dermatol Venereol. 2013;27(9):1101–1108. doi: 10.1111/J.1468-3083.2012.04668.X
  26. Mansouri Y, Martin-Clavijo A, Newsome P, Kaur MR. Dissecting cellulitis of the scalp treated with tumour necrosis factor-α inhibitors: Experience with two agents. British J Dermatol. 2016;174(4):916–918. doi: 10.1111/BJD.14269
  27. Martin-García RF, Rullán JM. Refractory dissecting cellulitis of the scalp successfully controlled with adalimumab. Puerto Rico Health Sci J. 2015;34(2):102–104.
  28. Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: Control of inflammation within residual structural disease. Arch Dermatol. 2010;146(5):517–520. doi: 10.1001/ARCHDERMATOL.2010.16
  29. Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory dissecting cellulitis of the scalp treated with adalimumab. J Drugs Dermatol. 2008;7(10):981–983.
  30. Jacobs F, Metzler G, Kubiak J, et al. New approach in combined therapy of perifolliculitis capitis abscedens et suffodiens. Acta Derm Venereol. 2011;91(6):726–727. doi: 10.2340/00015555-1146
  31. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-α inhibitors. Acta Derm Venereol. 2009;89(6):595–600. doi: 10.2340/00015555-0747
  32. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2009;15(5):280–294. doi: 10.1080/09546630410017275
  33. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. New Eng J Med. 2016;375(5):422–434. doi: 10.1056/nejmoa1504370
  34. Yiu ZZ, Madan V, Griffiths CE. Acne conglobata and adalimumab: Use of tumour necrosis factor-α antagonists in treatment-resistant acne conglobata, and review of the literature. Clin Exp Dermatol. 2015;40(4):383–386. doi: 10.1111/CED.12540
  35. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial. Ann Int Med. 2012;157(12):846–855. doi: 10.7326/0003-4819-157-12-201212180-00004
  36. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. British J Dermatol. 2011;165(2):391–398. doi: 10.1111/J.1365-2133.2011.10339.X
  37. Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Seminars Cutaneous Med Sur. 2017;36(2):47–54. doi: 10.12788/J.SDER.2017.017
  38. Campione E, Mazzotta AM, Bianchi L, Chimenti S. Severe acne successfully treated with etanercept. Acta Derm Venereol. 2006;86(3):256–257. doi: 10.2340/00015555-0046
  39. Schuttelaar ML, Leeman FW. Sustained remission of nodular inflammatory acne after treatment with infliximab. Clin Exp Dermatol. 2011;36(6):670–671. doi: 10.1111/J.1365-2230.2010.03998.X
  40. Shirakawa M, Uramoto K, Harada FA. Treatment of acne conglobata with infliximab. J Am Academy Dermatol. 2006;55(2):344–346. doi: 10.1016/J.JAAD.2005.06.008
  41. Marzano AV, Genovese G, Casazza G, et al. Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study. British J Dermatol. 2021;184(1):133–140. doi: 10.1111/BJD.18983
  42. Zouboulis CC. First real-world data provide evidence for a “window of opportunity” in treatment of hidradenitis suppurativa/acne inversa. British J Dermatol. 2021;184(1):10–11. doi: 10.1111/BJD.19165
  43. Martorell A, Caballero A, Lama YG, et al. Manejo del paciente con hidradenitis supurativa. Actas Dermosifiliogr. 2016;(107):32–42. doi: 10.1016/S0001-7310(17)30007-8
  44. Khobeish MM, Shustov DV, Sokolovsky EV. Hidradenitis suppurativa: Modern concepts of pathogenesis and therapy; successful experience of Adalimumab therapy. Vestnik Dermatologii i Venerologii. 2017;(5):70–81. (In Russ). doi: 10.25208/0042-4609-2017-93-5-70-81

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##